Medtronic has announced CE mark and FDA approval of its new Avalus pericardial aortic surgical valve for the treatment of aortic valve disease. According to a press release, valve leverages proven surgical bioprosthetic valve concepts with added features designed to enhance clinical performance, helping to address the contemporary needs of cardiac surgeons and patients.
SHS Gesellschaft für Beteiligungsmanagement is investing in CoreMedic, a start-up developing transfemoral repair systems to treat heart valve malfunctions. SHS is investing from its fourth fund generation to finance CoreMedic’s further growth and the clinical application of its innovative products.
Scott Montgomery (Örebro University, Örebro, Sweden) and colleagues report in the European Journal of Preventive Cardiology that pneumonia or sepsis in adults that results in hospital admission is associated with a six-fold increased risk of cardiovascular disease in the first year.
Keystone Heart has announced plans to initiate clinical trials for a new, advanced version of its TriGuard cerebral embolic protection device. A press release reports that this device—TriGuard 3—will continue the TriGuard legacy of being the only device designed to provide full coverage of all cerebral vessels while protecting the brain from embolic debris resulting from heart procedures, and also offer technological improvements over earlier versions of the device.
Medtronic has received the CE mark for its CoreValve Evolut Pro valve for the treatment of severe aortic stenosis for symptomatic patients who are at intermediate, high or extreme risk for open heart surgery. A press release reports that clinical data for the valve was presented at the American College of Cardiology annual Scientific Session (17–19 March, Washington, DC, USA) and showed high survival, low rates of stroke, minimal paravalvular leak and excellent haemodynamics.
Merit Medical will partner with internationally renowned interventional cardiologist Ferdinand Kiemeneij to deliver the next generation in educational opportunities for interventional cardiologists and interventional radiologists. Kiemeneij will serve as a co-proctor at the upcoming Advanced Transradial Intervention Education Course for Interventional Cardiologists (13–14 October, Merit Medical Education Cente, Salt Lake City, USA).
A new study, XIENCE Short DAPT, will evaluate whether three months of dual antiplatelet therapy (DAPT) is non-inferior to the standard duration of DAPT (12 months) in high bleeding risk patients who have undergone percutaneous coronary intervention (PCI) with an everolimus-eluting stent (Xience, Abbott Vascular). The study will enrol approximately 2,000 patients at 100 sites in the USA and Asia.
In a Viewpoint published in The Lancet, Pierre Carli (University Paris-Descartes, Paris, France; SAMU de Paris, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France) and others outline France’s medical response to terrorism. This follows a spate of terrorist attacks that have hit the country over the last two years.
Using a new imaging technique that can diagnose cardiac sarcoidosis much more accurately than traditional tests, researchers from the University of Illinois at Chicago (UIC), USA, have found that the disease affects other organs in 40% of affected patients. The findings are published in the Journal of Nuclear Cardiology.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion on a label update regarding the use of 15mg once-daily of the oral Factor Xa inhibitor rivaroxaban (Xarelto, Bayer) in combination with a P2Y12 inhibitor, for the treatment of patients with non-valvular atrial fibrillation (AF) who require oral anticoagulation and undergo percutaneous coronary intervention (PCI) with stent placement. The final decision of the European Commission is expected by the end of this year.
Taisei Kobayashi (Corporal Michael J Crescenz, Veterans Affairs Medical Center, Philadelphia, USA) and others report in JAMA Cardiology that—after adjustment for demographics, comorbidities and procedural characteristics—black patients do not have a significantly higher rate of one-year mortality after percutaneous coronary intervention (PCI) than do white patients. Previous studies have suggested that black patients have higher intermediate- and long-term adjusted mortality after PCI.
AstraZeneca has announced the UK availability of ticagrelor (Brilique) 90mg orodispersible tablets. This follows the European Commission’s marketing authorisation of the formulation in May 2017. A press release reports that ticagrelor is the first and only P2Y12 receptor antagonist to be made available in this form in the UK and Europe.
Plant-based diets are recommended to reduce the risk of heart disease; however, some plant-based diets are associated with a higher risk of heart disease, according to a study published in the Journal of the American College of Cardiology.
Innovative Cardiovascular Solutions has announced today completion of an oversubscribed Series B round of financing totalling US$5M. The company is currently developing the Emblok embolic protection system, which is designed for use in transcatheter aortic valve implantation (TAVI) and other structural heart procedures where embolic protection is required. Proceeds will be used for device development and initiation of a 510(k) clinical study in the USA.
Monika Safford (John J Kuiper Professor of Medicine and Chief of General Internal Medicine at Weill Cornell Medical College, New York, USA) and others report in Circulation that black people are twice as likely as white people to have fatal first cardiac event.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos